ArticleFrontiers in immunology2026
The paracrine effects of tumor cells on endothelial cells and macrophages in brain metastases with different primary sites.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain metastases (BrMs) represent the most common intracranial tumors, which occur at a significantly higher incidence than primary brain neoplasms. Although some studies addressed the modulation of endothelial cells (ECs) and macrophages in lung and breast BrMs, it is still unclear how these cells are modulated in other BrM types. Methods: Tumor cells (TCs) were isolated from human melanoma, lung and gastrointestinal (GI) BrM tissues, using individual patient isolates (n=2 per tissue origin) as the primary unit of inference. The paracrine effects of BrM-TCs on ECs and macrophages were examined in Results: None of the BrM-TCs had a direct effect on the ECs regarding MMP release, migration, proliferation and tubulogenesis. Interestingly, lung and GI but not melanoma BrM-TCs polarized macrophages into an M2-like phenotype, characterized by enhanced MMP9 release, increased Arg1 and CD206 expression, as well as elevated IL-6, IL-8, IL-10, and VEGF levels. Moreover, macrophages polarized by lung and GI but not melanoma BrM-TCs inhibited the proliferation of CD8 and CD4 T-cells. Conclusion: These findings indicate that lung and GI but not melanoma BrM-TCs polarize macrophages towards a tumor-promoting, M2-like phenotype. Although the direct effects of BrM-TCs on ECs remain to be further elucidated, our results highlight the need for further comparative studies on BrMs, with particular focus on their histological origins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.